NCT01253278已完成1 期
Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Effects of Multiple Escalating Oral Doses of LY2393910 in Patients With Type 2 Diabetes Mellitus
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 38
- 试验地点
- 1
- 主要终点
- Number of Participants with Clinically Significant Effects
研究概览
简要总结
The study drug LY2393910 is being evaluated as a possible treatment for diabetes. The primary purpose of a patient's participation in this study is to help answer the following research question(s), and not to provide treatment for diabetes:
- The safety of LY2393910 and any side effects that might be associated with it following 2 weeks of doses
- How long it takes the body to absorb and remove LY2393910 following dosing over 2 weeks
- How daily dosing of LY2393910 affects blood levels of sugar (glucose), insulin and other naturally occurring substances in your body
- How daily dosing of LY2393910 affects the cells that produce insulin
- Any differences in the above between LY2393910 taken as daily doses in the morning or in the evening
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 21 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Diagnosis of type 2 diabetes mellitus
- •Must be on a stable treatment regimen (maintained on diet/exercise therapy with or without metformin) for at least 4 weeks prior to study entry
- •Have a glycated haemoglobin (HbA1c) value greater than or equal to 6.5% and less than or equal to 10.0% on a stable treatment regimen
- •Weigh 45.0 kg or more
- •Have a Body Mass Index (BMI) greater than or equal to 18.5 and less than or equal to 40.0 kg/m2
- •Are willing and able to conduct self-blood glucose monitoring tests
排除标准
- •Are currently enrolled in, or discontinued within the last 30 days from a clinical trial involving use of an investigational drug or device other than the study drug used in this study, or are concurrently enrolled in any other type of medical research judged not to be compatible with this study
- •Use of insulin for diabetic control for more than 6 consecutive days within 1 year prior to study entry
- •Use of thiazolidinediones within 3 months, or other oral anti-diabetics (OADs), apart from metformin, within 1 month prior to study entry. Metformin is acceptable for this study
- •Previous myocardial infarction, stroke or transient ischaemic event ('TIA'), or clinically significant coronary events or symptoms within 6 months prior to study entry
- •Subjects who have any evidence of heart insufficiency, hypokalaemia, family history of long-QT-syndrome or are receiving other drugs which extend the QT interval
- •Clinically significant peripheral vascular disease
- •Clinical evidence of active diabetic proliferative retinopathy
- •Known significant autonomic neuropathy
- •Any patient having experienced a keto-acidotic episode requiring hospitalisation in the last 6 months
- •Symptomatic hyperglycemia exhibited by significant osmotic symptoms (polyuria or polydipsia), unanticipated weight loss or dehydration
- •Evidence of hepatitis B and/or positive hepatitis B surface antigen, at screening
- •Subjects who have an average weekly alcohol intake that exceeds 21 units per week (males) and 14 units per week (females)
- •Subjects who are heavy smokers (> 10 cigarettes, or equivalent, per day) or are unable or unwilling to refrain from nicotine during CRU admissions
- •Exclusion Criteria for EU Site only --
- •Regular use of known drugs of abuse and/or positive findings on urinary drug screening
- •Evidence of human immunodeficiency virus (HIV) and/or positive HIV antibodies
- •Evidence of hepatitis C and/or positive hepatitis C antibodies
研究组 & 干预措施
20 mg LY2393910
Experimental
干预措施: LY2393910 (Drug)
60 mg LY2393910
Experimental
干预措施: LY2393910 (Drug)
150 mg LY2393910
Experimental
干预措施: LY2393910 (Drug)
450 mg LY2393910
Experimental
干预措施: LY2393910 (Drug)
Placebo
Placebo Comparator
干预措施: Placebo (Drug)
结局指标
主要结局
Number of Participants with Clinically Significant Effects
时间窗: Over four weeks
次要结局
- Pharmacokinetics of LY2393910, Area Under the Curve (AUC)(From predose Day 1 up until Day 19)
- Change from baseline to day 28 in glucagon(Baseline, day 28)
- Pharmacokinetics of LY2393910, maximum concentration (Cmax)(From predose Day 1 up until Day 19)
- Change from baseline to day 28 in glucose-like peptide 1 (GLP-1)(Baseline, day 28)
- Change from baseline to day 14 in insulin(baseline, day 14)
- Change from baseline to day 14 in proinsulin(baseline, day 14)
- Change from baseline to day 28 in glucose(baseline, day 28)
- Change from baseline to day 14 in C-peptide(baseline, day 14)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
A Study of Multiple Increasing Doses of LY2409021 in Participants With Type 2 DiabetesDiabetes Mellitus, Type 2NCT01606397Eli Lilly and Company50
已完成
1 期
A Study to Compare the Concentrations of LY2189265 After Different Methods of Administration to Healthy Volunteers.Diabetes Mellitus, Type IINCT01301092Eli Lilly and Company30
已完成
1 期
A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese MenDiabetes Mellitus, Type 2NCT05870670Novo Nordisk A/S22
已完成
1 期
A Study of a New LY900014 Formulation in Healthy ParticipantsHealthyNCT02525744Eli Lilly and Company24
已完成
1 期
A Research Study of a New Medicine NNC0519-0130 in Healthy People, People With High Body Weight and People With Type 2 Diabetes.Healthy Volunteers (Diabetes Mellitus, Type 2)NCT05363774Novo Nordisk A/S161